Showing 2371-2380 of 10548 results for "".
Advocacy and Research
https://practicaldermatology.com/podcasts/practical-dermatology-podcasts/advocacy-and-research/36479/The latest news and updates, plus Harrison Nguyen, MD, MBA, MPH, FAAD, discusses addressing barriers to maximizing biologics for psoriasis, and Mark Lebwohl, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to talk about some of the latest research he has been involvAI for Patient Education and More
https://practicaldermatology.com/videos/c-suite-chats/ai-for-patient-education-and-more/36239/Anastasia Georgievskaya, founder of Haut.AI, discusses the impact of new artificial intelligence tools such as a virtual skincare try-on that shows customers how sunscreen and its ingredients will impact skin over time.HS Tips and Lizards
https://practicaldermatology.com/podcasts/practical-dermatology-podcasts/hs-tips-and-lizards/35858/The latest news and updates, plus a psoriasis update from Jashin J. Wu, MD, FAAD, at Music City SCALE, and Jennifer L. Hsiao, MD, joins Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, to discuss treating hidradenitis suppurativa and play a game of "Two Truths and a Lie."Masterclasses in Dermatology: The Importance of Interdisciplinary Teaching
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/masterclasses-in-dermatology-the-importance-of-interdisciplinary-teaching/33021/Masterclasses in Dermatology 2025 course directors Alice Gottlieb, MD, a dermatologist and rheumatologist at Mount Sinai, and Joseph Merola, MD, MMSc, chair and professor of dermatology at UT Southwestern Medical Center in Dallas, talk about the value of interdisciplinary education and collaborationThe Latest in Blistering Diseases
https://practicaldermatology.com/programs/practical-dermatology/the-latest-in-blistering-diseases/33007/Kim B. Yancey, MD, a professor of dermatology at UT Southwestern Medical Center in Dallas, talks about current treatments and techniques for blistering diseases, focusing specifically autoimmune blistering diseases.Updates in Cutaneous Lupus
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/updates-in-cutaneous-lupus/33008/Joseph Merola, MD, a dermatologist, rheumatologist, Chair and professor of dermatology at UT Southwestern Medical Center in Dallas, outlines his talks at Masterclasses in Dermatology talking about emerging therapies in cutaneous lupus.How to Ensure ‘People-First’ Content
https://practicaldermatology.com/issues/january-february-2025/how-to-ensure-people-first-content/32978/As members of the medical community, we have a strong sense of purpose and ethical responsibility to our patients and communities.Building an Inflammatory Clinic
https://practicaldermatology.com/videos/pa-perspectives/building-inflammatory-clinic/26436/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, discusses how to build an inflammatory clinic as an advanced practice practitioner (APP). Andrew also discusses what factors APPs should consider when prescribing mediDermWireTV: Dermatologists React to the Valisure Report; FDA Approves New Treatment for Frown Lines
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-dermatologists-react-valisure-report-fda-approves-new-treatment-frown-lines/24157/In this episode of DermWireTV, dermatologists react to the recent Valisure report that found elevated levels of benzene when studied under laboratory conditions in certain acne products containing BPO; the FDA approves a new treatment option for glabellar lines; and the PA Perspectives series addresDermWireTV: New Data Presented for Atopic Dermatitis and Prurigo Nodularis Candidates at AAD
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-new-data-presented-for-atopic-dermatitis-and-prurigo-nodularis-candidates-at-aad/24127/In this episode of DermWireTV, a phase 3 study finds roflumilast cream is associated with significantly improved atopic dermatitis in children; first-of-its-kind research suggests that eczema treatment lebrikizumab shows efficacy and safety in patients with skin of color; and new data reveals oral J